The Supreme Court is expected to take up the landmark case on Tuesday to resolve a decades-old dispute over how to fund medical research in the United States.
The justices, who were expected to rule in favor of the fund in November, are expected to decide whether to approve the plan to create a new fund for the creation of a $1 trillion fund for biomedical research, which could fund research in all fields of medicine and include drugs and vaccines, a major priority of President Donald Trump’s administration.
The fund, called the “International Monetary Fund,” was first proposed by the Clinton administration in 1997 to fund basic research.
The fund was first established in 1996 as part of the American Recovery and Reinvestment Act, or ARRA.
The new fund would provide for an annual $100 million allocation for the purpose of financing basic research in basic medicine, including clinical trials, basic research, research on diagnostics and treatments, and basic research and medical devices.
The $1.5 trillion fund is expected for launch by 2019.
The Obama administration had sought to create the fund, saying it was needed to fund the development of lifesaving drugs and treatments for cancer and other diseases.
The $1 billion fund was created by Congress to cover a shortfall in funding that the Obama administration estimated would cost the U.s. economy $8 billion annually.
The Trump administration is opposed to the creation, arguing that the fund is unnecessary and should be left to other countries, including the European Union.
The court has not ruled on the merits of the case.
The U.K. Supreme Judicial Court will rule on the matter next year.